Table 1 Graft characteristics and function in patients with at least 6 months follow‐up.
| Significant positive* | Non‐significant positive* | Negative* | p‐value† | |
|---|---|---|---|---|
| Number of patients | 11 | 5 | 40 | |
| Cadaveric kidneys | 10 | 4 | 37 | n.s. |
| Mean number of HLA mismatches | 3.27 | 2.6 | 2.68 | n.s. |
| Post‐transplant dialysis | 5 | 0 | 7 | n.s. |
| Campath induction | 7 | 3 | 24 | n.s. |
| Basiliximab induction | 4 | 2 | 16 | n.s. |
| MMF‡ | 9 | 5 | 38 | n.s. |
| Azathioprine§ | 2 | 0 | 2 | n.s. |
| 3‐month mean serum creatinine | 182 | 145 | 134 | 0.0025 |
| 3‐month median serum creatinine (range) | 165 (107–358) | 134 (104–218) | 123 (83–278) | |
| 6 month mean serum creatinine | 183 | 151 | 131 | 0.0014 |
| 6‐month median serum creatinine (range) | 151 (98–347) | 133 (108–251) | 129 (86–250) |
*Refers to urine cytology result; †Refers to comparison between significant positive and negative cases (Χ2 and Mann–Whitney U test); ‡Mycophenolate mofetil included in baseline immunosuppression; §Azathioprine included in baseline immunosuppression; n.s.: not significant.